Overcoming therapy resistance in EGFR-mutant lung cancer
Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …
[HTML][HTML] VEGF/VEGFR-targeted therapy and immunotherapy in non-small cell lung cancer: targeting the tumor microenvironment
Non-small cell lung cancer (NSCLC) is the leading cause of death by cancer worldwide.
Despite developments in therapeutic approaches for the past few decades, the 5-year …
Despite developments in therapeutic approaches for the past few decades, the 5-year …
[HTML][HTML] TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
Background Osimertinib is a potent, third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI). The multi-arm phase Ib TATTON study …
(EGFR) tyrosine kinase inhibitor (TKI). The multi-arm phase Ib TATTON study …
[HTML][HTML] Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC
The vascular endothelial growth factor (VEGF) pathway has been recognized as a key
mediator of angiogenesis to support tumorigenesis. Multiple therapeutic agents targeting …
mediator of angiogenesis to support tumorigenesis. Multiple therapeutic agents targeting …
A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy
The identification of molecular agents inhibiting specific functions in cancer cells
progression is considered as one of the most successful plans in cancer treatment. The …
progression is considered as one of the most successful plans in cancer treatment. The …
[HTML][HTML] Mechanisms of acquired resistance to first-and second-generation EGFR tyrosine kinase inhibitors
Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
I Otano, AC Ucero, J Zugazagoitia… - Nature reviews Clinical …, 2023 - nature.com
Non-small-cell lung cancer (NSCLC) has become a paradigm of precision medicine, with
the discovery of numerous disease subtypes defined by specific oncogenic driver mutations …
the discovery of numerous disease subtypes defined by specific oncogenic driver mutations …
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study
Q Zhou, CR Xu, Y Cheng, YP Liu, GY Chen, JW Cui… - Cancer cell, 2021 - cell.com
Dual inhibition of epidermal growth factor receptor (EGFR) and vascular endothelial growth
factor (VEGF) pathways may delay therapeutic resistance in advanced non-small cell lung …
factor (VEGF) pathways may delay therapeutic resistance in advanced non-small cell lung …
Efficacy of osimertinib plus bevacizumab vs osimertinib in patients with EGFR T790M–mutated non–small cell lung cancer previously treated with epidermal growth …
H Akamatsu, Y Toi, H Hayashi, D Fujimoto… - JAMA …, 2021 - jamanetwork.com
Importance Although treatment with first-generation epidermal growth factor receptor (EGFR)–
tyrosine kinase inhibitor (TKI) plus antiangiogenic inhibitor has shown promising efficacies …
tyrosine kinase inhibitor (TKI) plus antiangiogenic inhibitor has shown promising efficacies …
Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients
Cell-line screens create expansive datasets for learning predictive markers of drug
response, but these models do not readily translate to the clinic with its diverse contexts and …
response, but these models do not readily translate to the clinic with its diverse contexts and …